Cardiovascular Safety of Testosterone-Replacement Therapy

医学 睾酮替代 内科学 睾酮(贴片) 安全概况 重症监护医学 不利影响 雄激素 激素
作者
A. Michael Lincoff,Shalender Bhasin,Panagiotis Flevaris,Lisa M. Mitchell,Shehzad Basaria,William E. Boden,Glenn R. Cunningham,Christopher B. Granger,Mohit Khera,Ian M. Thompson,Qiuqing Wang,Kathy Wolski,Deborah Davey,Vidyasagar Kalahasti,Nader Khan,Michael G. Miller,Michael C. Snabes,Anna Chan,Elena Dubcenco,Xue Li
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:389 (2): 107-117 被引量:423
标识
DOI:10.1056/nejmoa2215025
摘要

BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined. METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who reported symptoms of hypogonadism and had two fasting testosterone levels of less than 300 ng per deciliter. Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter) or placebo gel. The primary cardiovascular safety end point was the first occurrence of any component of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-event analysis. A secondary cardiovascular end point was the first occurrence of any component of the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, assessed in a time-to-event analysis. Noninferiority required an upper limit of less than 1.5 for the 95% confidence interval of the hazard ratio among patients receiving at least one dose of testosterone or placebo. RESULTS: The mean (±SD) duration of treatment was 21.7±14.1 months, and the mean follow-up was 33.0±12.1 months. A primary cardiovascular end-point event occurred in 182 patients (7.0%) in the testosterone group and in 190 patients (7.3%) in the placebo group (hazard ratio, 0.96; 95% confidence interval, 0.78 to 1.17; P<0.001 for noninferiority). Similar findings were observed in sensitivity analyses in which data on events were censored at various times after discontinuation of testosterone or placebo. The incidence of secondary end-point events or of each of the events of the composite primary cardiovascular end point appeared to be similar in the two groups. A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group. CONCLUSIONS: In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
我爱吃菜发布了新的文献求助10
1秒前
CodeCraft的应助被lvy采纳,获得10
1秒前
1秒前
桐桐的应助被伯克利芙蓉王采纳,获得10
2秒前
啦啦啦发布了新的文献求助10
2秒前
顺利毕业完成签到,获得积分10
2秒前
JChengTwo发布了新的文献求助10
2秒前
2秒前
搜集达人的应助被玉米侠采纳,获得10
3秒前
haifeng发布了新的文献求助10
4秒前
贪玩仙人掌完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
火山发布了新的文献求助30
5秒前
Han发布了新的文献求助10
6秒前
JamesPei的应助被lvy采纳,获得10
6秒前
完美芯发布了新的文献求助10
6秒前
uppercrusteve完成签到,获得积分10
7秒前
卡卡发布了新的文献求助10
8秒前
8秒前
CYY发布了新的文献求助10
8秒前
alex完成签到,获得积分10
8秒前
9秒前
10秒前
10秒前
12秒前
James完成签到,获得积分10
12秒前
12秒前
酷波er的应助被lvy采纳,获得20
12秒前
13秒前
12111发布了新的文献求助10
13秒前
14秒前
思源的应助被JChengTwo采纳,获得10
14秒前
14秒前
Clarissa完成签到 ,获得积分10
15秒前
嘿嘿发布了新的文献求助10
15秒前
YN发布了新的文献求助10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188617
求助须知:如何正确求助?哪些是违规求助? 9576328
关于积分的说明 21846790
捐赠科研通 7786606
什么是DOI,文献DOI怎么找? 3435356
关于科研通互助平台的介绍 2559627
邀请新用户注册赠送积分活动 2482347